Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
OABI OmniAb
4.170-0.170-3.92%
Close
02/03 16:00 ET
4.1700.0000.00%
Post Mkt Price 02/03 16:04 ET
High
4.345
Open
4.290
Turnover
2.17M
Low
4.130
Pre Close
4.340
Volume
517.67K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Contrasting Charles River Laboratories International (NYSE:CRL) & OmniAb (NASDAQ:OABI)
Charles River Laboratories International (NYSE:CRL – Get Rating) and OmniAb (NASDAQ:OABI – Get Rating) are both medical companies, but which is the better investment? We will compare the two business
Head to Head Analysis: OmniAb (NASDAQ:OABI) Vs. U.S. Stem Cell (OTCMKTS:USRM)
OmniAb (NASDAQ:OABI – Get Rating) and U.S. Stem Cell (OTCMKTS:USRM – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on t
Comparing SomaLogic (NASDAQ:SLGC) & OmniAb (NASDAQ:OABI)
SomaLogic (NASDAQ:SLGC – Get Rating) and OmniAb (NASDAQ:OABI – Get Rating) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on
Reviewing OmniAb (NASDAQ:OABI) and SomaLogic (NASDAQ:SLGC)
OmniAb (NASDAQ:OABI – Get Rating) and SomaLogic (NASDAQ:SLGC – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the str
OmniAb (NASDAQ:OABI) Coverage Initiated at Truist Financial
Equities research analysts at Truist Financial initiated coverage on shares of OmniAb (NASDAQ:OABI – Get Rating) in a report released on Tuesday, The Fly reports. The brokerage set a "buy" rating and
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
UpgradesCanaccord Genuity upgraded the previous rating for Nevro Corp (NYSE:NVRO) from Hold to Buy. In the third quarter, Nevro showed an EPS of $0.59, compared to $0.87 from the year-ago quarter. The
Truist Starts OmniAb at Buy With $10 Price Target
09:02 AM EST, 12/20/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
OmniAb Price Target Announced at $10.00/Share by Truist Securities
OmniAb Price Target Announced at $10.00/Share by Truist Securities
Truist Securities Initiates Coverage On OmniAb With Buy Rating, Announces Price Target of $10
Truist Securities analyst Robyn Karnauskas initiates coverage on OmniAb (NASDAQ:OABI) with a Buy rating and announces Price Target of $10.
OmniAb Initiated With a Buy at Truist
Company Overview
More
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. The firm’s platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
CEO： Mr. Matthew W. Foehr
Market： NASDAQ
Listing Date： 08/10/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet